Copyright
©The Author(s) 2025.
World J Gastrointest Oncol. Jun 15, 2025; 17(6): 107700
Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.107700
Published online Jun 15, 2025. doi: 10.4251/wjgo.v17.i6.107700
Table 1 Pre-treatment staging system
| Stage | Specifics |
| PRETEXT/POST-TEXT I | Only one liver section is involved by the tumor |
| PRETEXT/POST-TEXT II | Tumor involves two contiguous sections of the liver |
| PRETEXT/POST-TEXT III | Tumor involves three liver sections, or two non-contiguous sections |
| PRETEXT/POST-TEXT IV | Tumor involves all four liver sections |
Table 2 Evan’s surgical stage
| Stage | Specifics |
| I | Complete gross resection with clear margins |
| II | Gross total resection with microscopic residual disease at margin of resection |
| III | Gross total resection with nodal involvement or tumor spill or incomplete resection with gross residual intrahepatic disease |
| IV | Metastatic disease with either complete or incomplete resection |
Table 3 Risk stratification criteria for hepatoblastoma
| Risk group | Stratification criteria | |
| Very low risk | Postoperative COG stage I with well-differentiated fetal histology | |
| Low risk | Meets any of the following | Serum AFP ≥ 100 ng/mL, PRETEXT stage I or II, and absence of high-risk features |
| Portal vein involvement (P+) | ||
| Inferior vena cava or hepatic vein involvement (V+) | ||
| Distant metastasis (M+) | ||
| Extrahepatic abdominal disease (E+) | ||
| Tumor rupture or intraperitoneal hemorrhage (H+) | ||
| Lymph node involvement (N+) | ||
| Postoperative COG stage I or II with non-pure fetal and non-small-cell undifferentiated histology | ||
| Intermediate risk | Meets any of the following | Preoperative PRETEXT stage III |
| Postoperative COG stage I or II with small-cell undifferentiated histology | ||
| Postoperative COG stage III | ||
| High risk | Meets any of the following | Serum AFP < 100 ng/mL |
| Preoperative PRETEXT stage IV | ||
| Postoperative COG stage IV | ||
| Portal vein (P+) or inferior vena cava/hepatic vein involvement (V+) | ||
- Citation: Tang R, Qi SQ, Zhang T, Pan ZB, Xu JH. Progress in the study of therapeutic strategies for hepatoblastoma in children. World J Gastrointest Oncol 2025; 17(6): 107700
- URL: https://www.wjgnet.com/1948-5204/full/v17/i6/107700.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v17.i6.107700
